|Clinical Trial Title||Juvenile Idiopathic Arthritis sub-types|
|Trial Status||Open to Enrollment|
|Trial Type||Pediatric Rheumatology|
|Specific Condition||Enthesitis-Related Arthritis (ERA) or Juvenile Psoriatic Arthritis (PSA) subtypes of JIA|
|Description||This is a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA) categories of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA). The study is divided into 3 parts (plus a post-treatment follow-up period) consisting of open-label, single-arm active treatment in Treatment Periods 1 and 3 and a randomized, double-blind, placebo controlled, event-driven withdrawal design in Treatment Period 2.
Other protocol-defined inclusion/exclusion criteria apply.
|Principal Investigator||Daniel Kingsbury, MD|
|Contact Name||Kristin Hickey|